Want to see EVAX full AI Analyst Report?
EVAX Stock Chart & Stats
$2.96
-$0.09(-2.95%)
At close: 4:00 PM EDT
$2.96
-$0.09(-2.95%)
Day’s Range― - ―
52-Week Range$2.52 - $12.15
Previous Close$2.96
Volume3.35K
Average Volume (3M)20.50K
Market Cap
$27.61M
Enterprise Value$18.96
Total Cash (Recent Filing)$18.44M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.73
Next Earnings
Nov 19, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding8,340,215
10 Day Avg. Volume13,703
30 Day Avg. Volume20,495
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.79
Price to Sales (P/S)4.06
P/FCF Ratio-4.59
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.67Price Target Upside294.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.01
Revenue Forecast (FY)$15.80M
Bulls Say, Bears Say
Bulls Say
EVX-01 Clinical DurabilityStrong response durability and tumor-specific immune activation provide meaningful clinical validation for Evaxion’s personalized vaccine approach. If sustained in three-year data, these results could strengthen partnering prospects and support future development of the lead asset.
AI Platform And Pipeline ExpansionThe platform is producing multiple vaccine candidates across oncology and infectious disease rather than relying on one asset. EVX-05’s Duke collaboration and shared ERV-targeting strategy may broaden the pipeline and improve research leverage over time.
Improved Capitalization And RunwayPositive equity, lower debt and a stated runway into H2 2027 give Evaxion time to advance clinical and preclinical programs. This reduces immediate balance-sheet pressure and allows value-creating milestones to be pursued before additional financing is required.
Bears Say
No Recurring Revenue And Ongoing LossesEvaxion remains dependent on external capital, partnerships or licensing rather than recurring product sales. Continued losses limit financial self-sufficiency and make the company’s long-term value highly dependent on successful clinical advancement and eventual commercialization.
Negative Cash Generation And Dilution RiskPersistent cash burn means the company cannot currently fund operations internally. Reliance on an ATM or future partnerships can extend development, but may dilute existing shareholders or create refinancing risk if clinical milestones or business-development activity are delayed.
Early-stage Regulatory And Development UncertaintySeveral pipeline programs remain preclinical or subject to manufacturing and regulatory milestones. Delays, failed studies or unresolved CMC requirements could postpone human testing, consume runway and reduce the probability that promising platform research becomes commercial medicine.
Evaxion Biotech News
EVAX FAQ
What was Evaxion Biotech A/S Adr’s price range in the past 12 months?
Evaxion Biotech A/S Adr lowest stock price was $2.52 and its highest was $12.15 in the past 12 months.
What is Evaxion Biotech A/S Adr’s market cap?
Evaxion Biotech A/S Adr’s market cap is $27.61M.
When is Evaxion Biotech A/S Adr’s upcoming earnings report date?
Evaxion Biotech A/S Adr’s upcoming earnings report date is Nov 19, 2026 which is in 88 days.
How were Evaxion Biotech A/S Adr’s earnings last quarter?
Evaxion Biotech A/S Adr released its earnings results on Aug 20, 2026. The company reported -$0.01 earnings per share for the quarter, the consensus estimate of -$0.01 by $0.
Is Evaxion Biotech A/S Adr overvalued?
According to Wall Street analysts Evaxion Biotech A/S Adr’s price is currently Undervalued.
Does Evaxion Biotech A/S Adr pay dividends?
Evaxion Biotech A/S Adr does not currently pay dividends.
What is Evaxion Biotech A/S Adr’s EPS estimate?
Evaxion Biotech A/S Adr’s EPS estimate is -0.01.
How many shares outstanding does Evaxion Biotech A/S Adr have?
Evaxion Biotech A/S Adr has 8,340,215 shares outstanding.
What happened to Evaxion Biotech A/S Adr’s price movement after its last earnings report?
Evaxion Biotech A/S Adr reported an EPS of -$0.01 in its last earnings report, expectations of -$0.01. Following the earnings report the stock price went up 4.127%.
Which hedge fund is a major shareholder of Evaxion Biotech A/S Adr?
Currently, no hedge funds are holding shares in EVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Evaxion Biotech A/S Adr
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
EVAX Company Deck
EVAX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial scientific and platform progress (strong EVX-01 immunogenicity and response data, new EVX-05 program, EVX-04 and EVX-V1 advances, and external validation of the personalized vaccine field). Financial discipline was highlighted and the cash runway was reconfirmed into H2 2027, with an ATM activated for optionality. Offsetting risks include a modest cash balance ($14.0M), a quarterly net loss of $3.7M, reliance on ATM/partnerships to extend runway, and early-stage status/timeline uncertainty for key new programs (EVX-05) and pending IND-enabling/CMC work for EVX-04.View all EVAX earnings summariesEVAX Stock 12 Month Forecast
Average Price Target
$11.67
▲(294.14% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
16.85% Other Institutional Investors
83.14% Public Companies and
Individual Investors